Abstract
The permeability of biological membranes is one of the most important determinants of the pharmacokinetic processes of a drug. Although it is often accepted that many drug substances are transported across biological membranes by passive transcellular diffusion, a recent hypothesis speculated that carrier-mediated mechanisms might account for the majority of membrane drug transport processes in biological systems. Based on evidence of the physicochemical characteristics and of in vitro and in vivo findings for marketed drugs, as well as results from real-life discovery and development projects, we present the view that both passive transcellular processes and carrier-mediated processes coexist and contribute to drug transport activities across biological membranes.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Dobson, P. D. & Kell, D. B. Carrier-mediated cellular uptake of pharmaceutical drugs: an exception or the rule? Nature Rev. Drug Discov. 7, 205–220 (2008).
Dobson, P. D., Lanthaler, K., Oliver, S. G. & Kell, D. B. Implications of the dominant role of transporters in drug uptake by cells. Curr. Top. Med. Chem. 9, 163–181 (2009).
Giacomini, K. M. et al. Membrane transporters in drug development. Nature Rev. Drug Discov. 9, 215–236 (2010).
Hoegerle, M. L. & Winne, D. Drug absorption by the rat jejunum perfused in situ. Dissociation from the pH-partition theory and role of microclimate-pH and unstirred layer. Naunyn Schmiedebergs Arch. Pharmacol. 322, 249–255 (1983).
Hogben, C. A., Tocco, D. J., Brodie, B. B. & Schanker, L. S. On the mechanism of intestinal absorption of drugs. J. Pharmacol. Exp. Ther. 125, 275–282 (1959).
Corti, G., Maestrelli, F., Cirri, M., Zerrouk, N. & Mura, P. Development and evaluation of an in vitro method for prediction of human drug absorption. Eur. J. Pharm. Sci. 27, 354–362 (2006).
Zhu, C., Jiang, L., Chen, T. M. & Hwang, K. K. A comparative study of artificial membrane permeability assay for high throughput profiling of drug absorption potential. Eur. J. Med. Chem. 37, 399–407 (2002).
Cohen, B. E. & Bangham, A. D. Diffusion of small nonelectrolytes across liposome membranes. Nature 236, 173–174 (1972).
Xiang, T. X. & Anderson, B. D. Influence of chain ordering on the selectivity of dipalmitoylphosphatidylcholine bilayer membranes for permeant size and shape. Biophys. J. 75, 2658–2671 (1998).
Meier, M., Blatter, X. L., Seelig, A. & Seelig, J. Interaction of verapamil with lipid membranes and P–glycoprotein: connecting thermodynamics and membrane structure with functional activity. Biophys. J. 91, 2943–2955 (2006).
Seelig, A. The role of size and charge for blood–brain barrier permeation of drugs and fatty acids. J. Mol. Neurosci. 33, 32–41 (2007).
Irvine, J. D. et al. MDCK (Madin–Darby canine kidney) cells: a tool for membrane permeability screening. J. Pharm. Sci. 88, 28–33 (1999).
Fredriksson, R., Nordstrom, K. J., Stephansson, O., Hagglund, M. G. & Schioth, H. B. The solute carrier (SLC) complement of the human genome: phylogenetic classification reveals four major families. FEBS Lett. 582, 3811–3816 (2008).
He, L., Vasiliou, K. & Nebert, D. W. Analysis and update of the human solute carrier (SLC) gene superfamily. Hum. Genomics 3, 195–206 (2009).
Van de Waterbeemd, H. in Comprehensive Medicinal Chemistry II Vol. 5 (eds Testa, B. & Van de Waterbeemd, H.) 669–697, (Elsevier Science, New York, 2006).
Chang, C., Ray, A. & Swaan, P. In silico strategies for modeling membrane transporter function. Drug Discov. Today 10, 663–671 (2005).
Wiese, M. & Pajeva, I. K. in Comprehensive Medicinal Chemistry II Vol. 5 (eds Testa, B. & Van de Waterbeemd, H.) 767–794 (Elsevier Science, New York, 2006).
Banerjee, A., Johnston, J. S. & Swaan, P. W. in Cellular Drug Delivery: Principles and Practice. Ch. 7 (eds Lu, D. R. & Oie, S.) 107–128 (Humana Press, New Jersey, 2004).
Lee, V. H. Membrane transporters. Eur. J. Pharm. Sci. 11, S41–S50 (2000).
Mueller, P., Rudin, D. O., Tien, H. T. & Wescott, W. C. Reconstitution of cell membrane structure in vitro and its transformation into an excitable system. Nature 194, 979–980 (1962).
Saparov, S. M., Antonenko, Y. N. & Pohl, P. A new model of weak acid permeation through membranes revisited: does Overton still rule? Biophys. J. 90, L86–L88 (2006).
Walter, A. & Gutknecht, J. Monocarboxylic acid permeation through lipid bilayer membranes. J. Membr. Biol. 77, 255–264 (1984).
Walter, A. & Gutknecht, J. Permeability of small nonelectrolytes through lipid bilayer membranes. J. Membr. Biol. 90, 207–217 (1986).
Paul, E. C., Hochman, J. & Quaroni, A. Conditionally immortalized intestinal epithelial cells: novel approach for study of differentiated enterocytes. Am. J. Physiol. 265, C266–C278 (1993).
Tavelin, S. et al. An improved cell culture model based on 2/4/A1 cell monolayers for studies of intestinal drug transport: characterization of transport routes. Pharm. Res. 20, 373–381 (2003).
Bermejo, M. et al. PAMPA — a drug absorption in vitro model 7. Comparing rat in situ, Caco-2, and PAMPA permeability of fluoroquinolones. Eur. J. Pharm. Sci. 21, 429–441 (2004).
Neuhoff, S., Ungell, A. L., Zamora, I. & Artursson, P. pH-dependent passive and active transport of acidic drugs across Caco-2 cell monolayers. Eur. J. Pharm. Sci. 25, 211–220 (2005).
Pade, V. & Stavchansky, S. Estimation of the relative contribution of the transcellular and paracellular pathway to the transport of passively absorbed drugs in the Caco-2 cell culture model. Pharm. Res. 14, 1210–1215 (1997).
Takanaga, H., Tamai, I. & Tsuji, A. pH-dependent and carrier-mediated transport of salicylic acid across Caco-2 cells. J. Pharm. Pharmacol. 46, 567–570 (1994).
Tsuji, A., Simanjuntak, M. T., Tamai, I. & Terasaki, T. pH-dependent intestinal transport of monocarboxylic acids: carrier-mediated and H+-cotransport mechanism versus pH-partition hypothesis. J. Pharm. Sci. 79, 1123–1124 (1990).
Kopplow, K., Letschert, K., Konig, J., Walter, B. & Keppler, D. Human hepatobiliary transport of organic anions analyzed by quadruple-transfected cells. Mol. Pharmacol. 68, 1031–1038 (2005).
Sasaki, M., Suzuki, H., Ito, K., Abe, T. & Sugiyama, Y. Transcellular transport of organic anions across a double-transfected Madin–Darby canine kidney II cell monolayer expressing both human organic anion-transporting polypeptide (OATP2/SLC21A6) and multidrug resistance-associated protein 2 (MRP2/ABCC2). J. Biol. Chem. 277, 6497–6503 (2002).
Lennernas, H. Human intestinal permeability. J. Pharm. Sci. 87, 403–410 (1998).
Lennernas, H. Intestinal permeability and its relevance for absorption and elimination. Xenobiotica 37, 1015–1051 (2007).
Lennernas, H. Modeling gastrointestinal drug absorption requires more in vivo biopharmaceutical data: experience from in vivo dissolution and permeability studies in humans. Curr. Drug Metab. 8, 645–657 (2007).
Collett, A., Tanianis-Hughes, J., Hallifax, D. & Warhurst, G. Predicting P-glycoprotein effects on oral absorption: correlation of transport in Caco-2 with drug pharmacokinetics in wild-type and mdr1a−/− mice in vivo. Pharm. Res. 21, 819–826 (2004).
Avdeef, A. et al. Caco-2 permeability of weakly basic drugs predicted with the double-sink PAMPA pKaflux method. Eur. J. Pharm. Sci. 24, 333–349 (2005).
Matsson, P., Pedersen, J. M., Norinder, U., Bergstroem, C. A. & Artursson, P. Identification of novel specific and general inhibitors of the three major human ATP-binding cassette transporters P-gp, BCRP and MRP2 among registered drugs. Pharm. Res. 26, 1816–1831 (2009).
Kim, R. B. et al. Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharm. Res. 16, 408–414 (1999).
Kansy, M., Senner, F. & Gubernator, K. Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes. J. Med. Chem. 41, 1007–1010 (1998).
Avdeef, A., Kansy, M., Bendels, S. & Tsinman, K. Absorption–excipient–pH classification gradient maps: sparingly soluble drugs and the pH partition hypothesis. Eur. J. Pharm. Sci. 33, 29–41 (2008).
Nielsen, P. E. & Avdeef, A. PAMPA — a drug absorption in vitro model 8. Apparent filter porosity and the unstirred water layer. Eur. J. Pharm. Sci. 22, 33–41 (2004).
Sugano, K. in Comprehensive Medicinal Chemistry II Vol. 5 (eds Testa, B. & Van de Waterbeemd, H.) 453–487 (Elsevier, Oxford, 2007).
Artursson, P. & Borchardt, R. T. Intestinal drug absorption and metabolism in cell cultures: Caco-2 and beyond. Pharm. Res. 14, 1655–1658 (1997).
Englund, G. et al. Regional levels of drug transporters along the human intestinal tract: co-expression of ABC and SLC transporters and comparison with Caco-2 cells. Eur. J. Pharm. Sci. 29, 269–277 (2006).
Hilgendorf, C. et al. Expression of thirty-six drug transporter genes in human intestine, liver, kidney, and organotypic cell lines. Drug Metab. Dispos. 35, 1333–1340 (2007).
Hubatsch, I., Ragnarsson, E. G. & Artursson, P. Determination of drug permeability and prediction of drug absorption in Caco-2 monolayers. Nature Protoc. 2, 2111–2119 (2007).
Neuhoff, S., Ungell, A.-L., Zamora, I. & Artursson, P. pH-dependent bidirectional transport of weakly basic drugs across Caco-2 monolayers: implications for drug-drug interactions. Pharm. Res. 20, 1141–1148 (2003).
Pickett, S. D., McLay, I. M. & Clark, D. E. Enhancing the hit-to-lead properties of lead optimization libraries. J. Chem. Inf. Comput. Sci. 40, 263–272 (2000).
Feng, B. et al. In vitro P-glycoprotein assays to predict the in vivo interactions of P-glycoprotein with drugs in the central nervous system. Drug Metab. Dispos. 36, 268–275 (2008).
Thiel-Demby, V. E. et al. Biopharmaceutics classification system: validation and learnings of an in vitro permeability assay. Mol. Pharm. 6, 11–18 (2009).
Volpe, D. A. Variability in Caco-2 and MDCK cell-based intestinal permeability assays. J. Pharm. Sci. 97, 712–725 (2008).
Hayeshi, R. et al. Comparison of drug transporter gene expression and functionality in Caco-2 cells from 10 different laboratories. Eur. J. Pharm. Sci. 35, 383–396 (2008).
Sugano, K., Takata, N., Machida, M., Saitoh, K. & Terada, K. Prediction of passive intestinal absorption using bio-mimetic artificial membrane permeation assay and the paracellular pathway model. Int. J. Pharm. 241, 241–251 (2002).
Avdeef, A. et al. Parallel artificial membrane permeability assay (PAMPA)-critical factors for better predictions of absorption. J. Pharm. Sci. 96, 2893–2909 (2007).
Galinis-Luciani, D., Nguyen, L. & Yazdanian, M. Is parallel artificial membrane permeability assay a useful tool for discovery? J. Pharm. Sci. 96, 2886–2892 (2007).
Rautio, J., Laine, K. & Gynther, M. Enhanced brain drug delivery and targeting. Pharm. Technol. Eur. 20, 27–29, 32–33 (2008).
Sugano, K., Nabuchi, Y., Machida, M. & Asoh, Y. Permeation characteristics of a hydrophilic basic compound across a bio-mimetic artificial membrane. Int. J. Pharm. 275, 271–278 (2004).
Takagi, M. et al. A new interpretation of salicylic acid transport across the lipid bilayer: implications of pH-dependent but not carrier-mediated absorption from the gastrointestinal tract. J. Pharmacol. Exp. Ther. 285, 1175–1180 (1998).
Valko, K. & Reynolds, D. P. High-throughput physicochemical and in vitro ADMET screening: a role in pharmaceutical profiling. Am. J. Drug Deliv. 3, 83–100 (2005).
Gustafsson, D. et al. The direct thrombin inhibitor melagatran and its oral prodrug H 376/95: intestinal absorption properties, biochemical and pharmacodynamic effects. Thromb. Res. 101, 171–181 (2001).
Sugano, K. et al. Quantitative structure–intestinal permeability relationship of benzamidine analogue thrombin inhibitor. Bioorg. Med. Chem. Lett. 10, 1939–1942 (2000).
Fischer, H., Kansy, M., Avdeef, A. & Senner, F. Permeation of permanently positive charged molecules through artificial membranes — influence of physico-chemical properties. Eur. J. Pharm. Sci. 31, 32–42 (2007).
Ruifrok, P. G. & Meijer, D. K. Transport of organic ions through lipid bilayers. Naunyn Schmiedebergs Arch. Pharmacol. 316, 266–272 (1981).
Poirier, A. et al. Design, data analysis and simulation of in vitro drug transport kinetic experiments using a mechanistic in vitro model. Drug Metab. Dispos. 36, 2434–2444 (2008).
Lei, Y. D., Wania, F., Shiu, W. Y. & Boocock, D. G. B. HPLC-based method for estimating the temperature dependence of n-Octanol–water partition coefficients. J. Chem. Eng. Data 45, 738–742 (2000).
Tanaka, M., Fukuda, H. & Nagai, T. Permeation of a drug through a model membrane consisting of millipore filter with oil. Chem. Pharm. Bull. 26, 9–13 (1978).
Raeissi, S. D., Li, J. & Hidalgo, I. J. The role of an α-amino group on H+-dependent transepithelial transport of cephalosporins in Caco-2 cells. J. Pharm. Pharmacol. 51, 35–40 (1999).
Takacs-Novak, K., Box, K. J. & Avdeef, A. Potentiometric pKa determination of water-insoluble compounds: validation study in methanol/water mixtures. Int. J. Pharm. 151, 235–248 (1997).
Said, H. M., Blair, J. A., Lucas, M. L. & Hilburn, M. E. Intestinal surface acid microclimate in vitro and in vivo in the rat. J. Lab. Clin. Med. 107, 420–424 (1986).
Xiang, T. X. & Anderson, B. D. Substituent contributions to the transport of substituted p-toluic acids across lipid bilayer membranes. J. Pharm. Sci. 83, 1511–1518 (1994).
Cohen, B. E. Permeability of liposomes to nonelectrolytes. II. Effect of nystatin and gramicidin A. J. Membr. Biol. 20, 235–268 (1975).
Cao, Y., Xiang, T.-X. & Anderson, B. D. Development of structure–lipid bilayer permeability relationships for peptide-like small organic molecules. Mol. Pharm. 5, 371–388 (2008).
Camenisch, G., Alsenz, J., van de Waterbeemd, H. & Folkers, G. Estimation of permeability by passive diffusion through Caco-2 cell monolayers using the drugs' lipophilicity and molecular weight. Eur. J. Pharm. Sci. 6, 313–319 (1998).
Johnson, T. W., Dress, K. R. & Edwards, M. Using the Golden Triangle to optimize clearance and oral absorption. Bioorg. Med. Chem. Lett. 19, 5560–5564 (2009).
Linnankoski, J., Ranta, V.-P., Yliperttula, M. & Urtti, A. Passive oral drug absorption can be predicted more reliably by experimental than computational models — fact or myth. Eur. J. Pharm. Sci. 34, 129–139 (2008).
Lombardo, F., Obach, R. S., Shalaeva, M. Y. & Gao, F. Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data. J. Med. Chem. 45, 2867–2876 (2002).
Martin, Y. C. A practitioner's perspective of the role of quantitative structure–activity analysis in medicinal chemistry. J. Med. Chem. 24, 229–237 (1981).
Obach, R. S., Lombardo, F. & Waters, N. J. Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Drug Metab. Dispos. 36, 1385–1405 (2008).
Obata, K. et al. Prediction of oral drug absorption in humans by theoretical passive absorption model. Int. J. Pharm. 293, 183–192 (2005).
Rodgers, T. & Rowland, M. Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions. J. Pharm. Sci. 95, 1238–1257 (2006).
Rodgers, T. & Rowland, M. Mechanistic approaches to volume of distribution predictions: understanding the processes. Pharm. Res. 24, 918–933 (2007).
Veber, D. F. et al. Molecular properties that influence the oral bioavailability of drug candidates. J. Med. Chem. 45, 2615–2623 (2002).
Winiwarter, S. et al. Correlation of human jejunal permeability (in vivo) of drugs with experimentally and theoretically derived parameters. A multivariate data analysis approach. J. Med. Chem. 41, 4939–4949 (1998).
Reynolds, D. P., Lanevskij, K., Japertas, P., Didziapetris, R. & Petrauskas, A. Ionization-specific analysis of human intestinal absorption. J. Pharm. Sci. 98, 4039–4054 (2009).
Fischer, H., Gottschlich, R. & Seelig, A. Blood–brain barrier permeation: molecular parameters governing passive diffusion. J. Membr. Biol. 165, 201–211 (1998).
Gratton, J. A., Abraham, M. H., Bradbury, M. W. & Chadha, H. S. Molecular factors influencing drug transfer across the blood–brain barrier. J. Pharm. Pharmacol. 49, 1211–1216 (1997).
Hou, T. J., Zhang, W., Xia, K., Qiao, X. B. & Xu, X. J. ADME evaluation in drug discovery. 5. Correlation of Caco-2 permeation with simple molecular properties. J. Chem. Inf. Comput. Sci. 44, 1585–1600 (2004).
Palm, K. et al. Evaluation of dynamic polar molecular surface area as predictor of drug absorption: comparison with other computational and experimental predictors. J. Med. Chem. 41, 5382–5392 (1998).
Zhao, Y. et al. Evaluation of human intestinal absorption data and subsequent derivation of a quantitative structure–activity relationship (QSAR) with the Abraham descriptors. J. Pharm. Sci. 90, 749–784 (2001).
Avdeef, A. in Absorption and Drug Development: Solubility, Permeability and Charge State 1–312 (Wiley-Interscience, Hoboken, New Jersey, 2003).
Camenisch, G., Folkers, G. & van de Waterbeemd, H. Comparison of passive drug transport through Caco-2 cells and artificial membranes. Int. J. Pharm. 147, 61–70 (1997).
Dagenais, C., Avdeef, A., Tsinman, O., Dudley, A. & Beliveau, R. P-glycoprotein deficient mouse in situ blood–brain barrier permeability and its prediction using an in combo PAMPA model. Eur. J. Pharm. Sci. 38, 121–137 (2009).
Di, L., Kerns, E. H., Bezar, I. F., Petusky, S. L. & Huang, Y. Comparison of blood–brain barrier permeability assays: in situ brain perfusion, MDR1–MDCKII and PAMPA–BBB. J. Pharm. Sci. 98, 1980–1991 (2009).
Di, L., Kerns, E. H., Fan, K., McConnell, O. J. & Carter, G. T. High throughput artificial membrane permeability assay for blood–brain barrier. Eur. J. Med. Chem. 38, 223–232 (2003).
Flaten, G. E., Dhanikula, A. B., Luthman, K. & Brandl, M. Drug permeability across a phospholipid vesicle based barrier: a novel approach for studying passive diffusion. Eur. J. Pharm. Sci. 27, 80–90 (2006).
Kerns, E. H. et al. Combined application of parallel artificial membrane permeability assay and Caco-2 permeability assays in drug discovery. J. Pharm. Sci. 93, 1440–1453 (2004).
Kwon, J.-H. & Escher, B. I. A modified parallel artificial membrane permeability assay for evaluating the bioconcentration of highly hydrophobic chemicals in fish. Environ. Sci. Technol. 42, 1787–1793 (2008).
Li, C. et al. Correlation between PAMPA permeability and cellular activities of hepatitis C virus protease inhibitors. Biochem. Pharmacol. 75, 1186–1197 (2008).
Matsson, P. et al. Exploring the role of different drug transport routes in permeability screening. J. Med. Chem. 48, 604–613 (2005).
Miret, S., Abrahamse, L. & de Groene, E. M. Comparison of in vitro models for the prediction of compound absorption across the human intestinal mucosa. J. Biomol. Screen. 9, 598–606 (2004).
Ottaviani, G., Martel, S. & Carrupt, P.-A. Parallel artificial membrane permeability assay: a new membrane for the fast prediction of passive human skin permeability. J. Med. Chem. 49, 3948–3954 (2006).
Saitoh, R. et al. Correction of permeability with pore radius of tight junctions in Caco-2 monolayers improves the prediction of the dose fraction of hydrophilic drugs absorbed by humans. Pharm. Res. 21, 749–755 (2004).
Sugano, K., Hamada, H., Machida, M. & Ushio, H. High throuput prediction of oral absorption: improvement of the composition of the lipid solution used in parallel artificial membrane permeation assay. J. Biomol. Screen. 6, 189–196 (2001).
Sugano, K., Nabuchi, Y., Machida, M. & Aso, Y. Prediction of human intestinal permeability using artificial membrane permeability. Int. J. Pharm. 257, 245–251 (2003).
Wohnsland, F. & Faller, B. High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes. J. Med. Chem. 44, 923–930 (2001).
Avdeef, A. The rise of PAMPA. Expert Opin. Drug Metab. Toxicol. 1, 325–342 (2005).
Beigi, F. et al. Immobilized liposome and biomembrane partitioning chromatography of drugs for prediction of drug transport. Int. J. Pharm. 164, 129–137 (1998).
Danelian, E. et al. SPR biosensor studies of the direct interaction between 27 drugs and a liposome surface: correlation with fraction absorbed in humans. J. Med. Chem. 43, 2083–2086 (2000).
Loidl-Stahlhofen, A., Eckert, A., Hartmann, T. & Schottner, M. Solid-supported lipid membranes as a tool for determination of membrane affinity: high-throughput screening of a physicochemical parameter. J. Pharm. Sci. 90, 599–606 (2001).
Pidgeon, C. et al. IAM chromatography: an in vitro screen for predicting drug membrane permeability. J. Med. Chem. 38, 590–594 (1995).
Ano, R. et al. Relationships between structure and high-throughput screening permeability of peptide derivatives and related compounds with artificial membranes: application to prediction of Caco-2 cell permeability. Bioorg. Med. Chem. 12, 257–264 (2004).
Fujikawa, M., Nakao, K., Shimizu, R. & Akamatsu, M. QSAR study on permeability of hydrophobic compounds with artificial membranes. Bioorg. Med. Chem. 15, 3756–3767 (2007).
Kansy, M. et al. in Pharmacokinetic Optimization in Drug Research: Biological, Physicochemical and Computational Strategies (eds Testa, B., Van de Waterbeemd, H., Folkers, G. & Guy, R.) 447–464 (Wiley-VCH, Zurich, 2001).
Kubinyi, H. Drug partitioning: relationships between forward and reverse rate constants and partition coefficient. J. Pharm. Sci. 67, 262–263 (1978).
Kubinyi, H. Lipophilicity and drug activity. Prog. Drug Res. 23, 97–198 (1979).
Wenlock, M. C., Austin, R. P., Barton, P., Davis, A. M. & Leeson, P. D. A comparison of physiochemical property profiles of development and marketed oral drugs. J. Med. Chem. 46, 1250–1256 (2003).
Balimane, P. V. et al. Peptide transporter substrate identification during permeability screening in drug discovery: comparison of transfected MDCK-hPepT1 cells to Caco-2 cells. Arch. Pharm. Res. 30, 507–518 (2007).
Balimane, P. V. et al. A novel high-throughput automated chip-based nanoelectrospray tandem mass spectrometric method for PAMPA sample analysis. J. Pharm. Biomed. Anal. 39, 8–16 (2005).
Di, L. & Kerns, E. H. Profiling drug-like properties in discovery research. Curr. Opin. Chem. Biol. 7, 402–408 (2003).
Sugano, K., Obata, K., Saitoh, R., Higashida, A. & Hamada, H. in Pharmacokinetic Profiling in Drug Research (eds Testa, B., Krämer, S., Wunderli-Allenspach, H. & Folkers, G.) 441–458 (Wiley-VCH, Zurich, 2006).
Masungi, C. et al. Parallel artificial membrane permeability assay (PAMPA) combined with a 10-day multiscreen Caco-2 cell culture as a tool for assessing new drug candidates. Pharmazie 63, 194–199 (2008).
Tavelin, S. et al. Prediction of the oral absorption of low-permeability drugs using small intestine-like 2/4/A1 cell monolayers. Pharm. Res. 20, 397–405 (2003).
Lagas, J. S., Vlaming, M. L. & Schinkel, A. H. Pharmacokinetic assessment of multiple ATP-binding cassette transporters: the power of combination knockout mice. Mol. Interv. 9, 136–145 (2009).
van de Steeg, E. et al. Methotrexate pharmacokinetics in transgenic mice with liver-specific expression of human organic anion-transporting polypeptide 1B1 (SLCO1B1). Drug Metab. Dispos. 37, 277–281 (2009).
Chen, C., Liu, X. & Smith, B. J. Utility of Mdr1-gene deficient mice in assessing the impact of P-glycoprotein on pharmacokinetics and pharmacodynamics in drug discovery and development. Curr. Drug Metab. 4, 272–291 (2003).
Chiou, W. L., Chung, S. M. & Wu, T. C. Apparent lack of effect of P-glycoprotein on the gastrointestinal absorption of a substrate, tacrolimus, in normal mice. Pharm. Res. 17, 205–208 (2000).
del Amo, E. M., Heikkinen, A. T. & Moenkkoenen, J. In vitro–in vivo correlation in P-glycoprotein mediated transport in intestinal absorption. Eur. J. Pharm. Sci. 36, 200–211 (2009).
Kato, Y. et al. Investigation of the role of oligopeptide transporter PEPT1 and sodium/glucose cotransporter SGLT1 in intestinal absorption of their substrates using small GTP-binding protein Rab8-null mice. Drug Metab. Dispos. 37, 602–607 (2009).
Hironaka, T., Itokawa, S., Ogawara, K., Higaki, K. & Kimura, T. Quantitative evaluation of PEPT1 contribution to oral absorption of cephalexin in rats. Pharm. Res. 26, 40–50 (2009).
Johnson, W. W. P-glycoprotein-mediated efflux as a major factor in the variance of absorption and distribution of drugs: modulation of chemotherapy resistance. Methods Find. Exp. Clin. Pharmacol. 24, 501–514 (2002).
Brandsch, M., Knutter, I. & Bosse-Doenecke, E. Pharmaceutical and pharmacological importance of peptide transporters. J. Pharm. Pharmacol. 60, 543–585 (2008).
Knutter, I. et al. Transport of angiotensin-converting enzyme inhibitors by H+/peptide transporters revisited. J. Pharmacol. Exp. Ther. 327, 432–441 (2008).
Brandsch, M. Transport of drugs by proton-coupled peptide transporters: pearls and pitfalls. Expert Opin. Drug Metab. Toxicol. 5, 887–905 (2009).
Schoenmakers, R. G., Stehouwer, M. C. & Tukker, J. J. Structure–transport relationship for the intestinal small-peptide carrier: is the carbonyl group of the peptide bond relevant for transport? Pharm. Res. 16, 62–68 (1999).
Cao, X. et al. Why is it challenging to predict intestinal drug absorption and oral bioavailability in human using rat model. Pharm. Res. 23, 1675–1686 (2006).
Chiou, W. L., Chung, S. M., Wu, T. C. & Ma, C. A comprehensive account on the role of efflux transporters in the gastrointestinal absorption of 13 commonly used substrate drugs in humans. Int. J. Clin. Pharmacol. Ther. 39, 93–101 (2001).
Kwon, H., Lionberger, R. A. & Yu, L. X. Impact of P-glycoprotein-mediated intestinal efflux kinetics on oral bioavailability of P-glycoprotein substrates. Mol. Pharm. 1, 455–465 (2004).
Amidon, G. L., Lennernas, H., Shah, V. P. & Crison, J. R. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res. 12, 413–420 (1995).
Lin, J. H. & Yamazaki, M. Role of P-glycoprotein in pharmacokinetics: clinical implications. Clin. Pharmacokinet. 42, 59–98 (2003).
Cao, X. et al. Permeability dominates in vivo intestinal absorption of P-gp substrate with high solubility and high permeability. Mol. Pharm. 2, 329–340 (2005).
Doppenschmitt, S., Spahn-Langguth, H., Regardh, C. G. & Langguth, P. Role of P-glycoprotein-mediated secretion in absorptive drug permeability: an approach using passive membrane permeability and affinity to P-glycoprotein. J. Pharm. Sci. 88, 1067–1072 (1999).
Lentz, K. A., Polli, J. W., Wring, S. A., Humphreys, J. E. & Polli, J. E. Influence of passive permeability on apparent P-glycoprotein kinetics. Pharm. Res. 17, 1456–1460 (2000).
Varma, M. V., Sateesh, K. & Panchagnula, R. Functional role of P-glycoprotein in limiting intestinal absorption of drugs: contribution of passive permeability to P-glycoprotein mediated efflux transport. Mol. Pharm. 2, 12–21 (2005).
von Richter, O. et al. A novel screening strategy to identify ABCB1 substrates and inhibitors. Naunyn Schmiedebergs Arch. Pharmacol. 379, 11–26 (2009).
Faller, B. in Hit and Lead Profiling. Identification and Optimization of Drug-like Molecules. Methods and Principles in Medicinal Chemistry Vol. 43 (eds Faller, B. & Laszlo, U.) (Wiley VCH, Weinheim 2009).
Sun, H. & Pang, K. S. Permeability, transport, and metabolism of solutes in Caco-2 cell monolayers: a theoretical study. Drug Metab. Dispos. 36, 102–123 (2008).
Eytan, G. D. Mechanism of multidrug resistance in relation to passive membrane permeation. Biomed. Pharmacother. 59, 90–97 (2005).
Wu, C.-Y. & Benet, L. Z. Predicting drug disposition via application of BCS: transport/absorption/ elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm. Res. 22, 11–23 (2005).
Fenner, K. S. et al. Drug–drug interactions mediated through P-glycoprotein: clinical relevance and in vitro–in vivo correlation using digoxin as a probe drug. Clin. Pharmacol. Ther. 85, 173–181 (2009).
Oh, D.-M., Curl, R. L., Yong, C.-S. & Amidon, G. L. Effect of micronization on the extent of drug absorption from suspensions in humans. Arch. Pharm. Res. 18, 427–433 (1995).
Shaw, T. R. & Carless, J. E. Effect of particle size on the absorption of digoxin. Eur. J. Clin. Pharmacol. 7, 269–273 (1974).
Yu, L. X. An integrated model for determining causes of poor oral drug absorption. Pharm. Res. 16, 1883–1887 (1999).
Ogihara, T. et al. What kinds of substrates show P-glycoprotein-dependent intestinal absorption? Comparison of verapamil with vinblastine. Drug Metab. Pharmacokinet. 21, 238–244 (2006).
Nagahara, N., Tavelin, S. & Artursson, P. Contribution of the paracellular route to the pH-dependent epithelial permeability to cationic drugs. J. Pharm. Sci. 93, 2972–2984 (2004).
Lafforgue, G. et al. Oral absorption of ampicillin: role of paracellular route vs. PepT1 transporter. Fund. Clin. Pharmacol. 22, 189–201 (2008).
Linnankoski, J. et al. Paracellular porosity and pore size of the human intestinal epithelium in tissue and cell culture models. J. Pharm. Sci. 99 (Suppl. 4), 2166–2175 (2010).
Eytan, G. D., Regev, R., Oren, G. & Assaraf, Y. G. The role of passive transbilayer drug movement in multidrug resistance and its modulation. J. Biol. Chem. 271, 12897–12902 (1996).
Fagerholm, U. The role of permeability in drug ADME/PK, interactions and toxicity — presentation of a permeability-based classification system (PCS) for prediction of ADME/PK in humans. Pharm. Res. 25, 625–638 (2008).
Kohl, C. Transporters — the view from industry. Chem. Biodivers. 6, 1988–1999 (2009).
Scherrmann, J. M. Transporters in absorption, distribution, and elimination. Chem. Biodivers. 6, 1933–1942 (2009).
Shugarts, S. & Benet, L. Z. The role of transporters in the pharmacokinetics of orally administered drugs. Pharm. Res. 26, 2039–2054 (2009).
Petri, N., Tannergren, C., Rungstad, D. & Lennernaes, H. Transport characteristics of fexofenadine in the Caco-2 cell model. Pharm. Res. 21, 1398–1404 (2004).
Cvetkovic, M., Leake, B., Fromm, M. F., Wilkinson, G. R. & Kim, R. B. OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab. Dispos. 27, 866–871 (1999).
Tannergren, C., Knutson, T., Knutson, L. & Lennernas, H. The effect of ketoconazole on the in vivo intestinal permeability of fexofenadine using a regional perfusion technique. Br. J. Clin. Pharmacol. 55, 182–190 (2003).
Glaeser, H. et al. Intestinal drug transporter expression and the impact of grapefruit juice in humans. Clin. Pharmacol. Ther. 81, 362–370 (2007).
Russel, T., Stoltz, M. & Weir, S. Pharmacokinetics, pharmacodynamics, and tolerance of single- and multiple-dose fexofenadine hydrochloride in healthy male volunteers. Clin. Pharmacol. Ther. 64, 612–621 (1998).
Lappin, G. et al. Pharmacokinetics of fexofenadine: evaluation of a microdose and assessment of absolute oral bioavailability. Eur. J. Pharm. Sci. 40, 125–131 (2010).
Korjamo, T., Kemilainen, H., Heikkinen, A. T. & Monkkonen, J. Decrease in intracellular concentration causes the shift in Km value of efflux pump substrates. Drug Metab. Dispos. 35, 1574–1579 (2007).
Tachibana, T. et al. Model analysis of the concentration-dependent permeability of P-gp substrates. Pharm. Res. 27, 442–446 (2010).
Trotter, P. J. & Storch, J. Fatty acid uptake and metabolism in a human intestinal cell line (Caco-2): comparison of apical and basolateral incubation. J. Lipid Res. 32, 293–304 (1991).
Troutman, M. D. & Thakker, D. R. Novel experimental parameters to quantify the modulation of absorptive and secretory transport of compounds by P-glycoprotein in cell culture models of intestinal epithelium. Pharm. Res. 20, 1210–1224 (2003).
Troutman, M. D. & Thakker, D. R. Efflux ratio cannot assess P-glycoprotein-mediated attenuation of absorptive transport: asymmetric effect of P-glycoprotein on absorptive and secretory transport across Caco-2 cell monolayers. Pharm. Res. 20, 1200–1209 (2003).
Bailey, D. G., Dresser, G. K., Leake, B. F. & Kim, R. B. Naringin is a major and selective clinical inhibitor of organic anion-transporting polypeptide 1A2 (OATP1A2) in grapefruit juice. Clin. Pharmacol. Ther. 81, 495–502 (2007).
Yasui-Furukori, N., Uno, T., Sugawara, K. & Tateishi, T. Different effects of three transporting inhibitors, verapamil, cimetidine, and probenecid, on fexofenadine pharmacokinetics. Clin. Pharmacol. Ther. 77, 17–23 (2005).
Kikuchi, A., Nozawa, T., Wakasawa, T., Maeda, T. & Tamai, I. Transporter-mediated intestinal absorption of fexofenadine in rats. Drug Metab. Pharmacokinet. 21, 308–314 (2006).
Tannergren, C. et al. Multiple transport mechanisms involved in the intestinal absorption and first-pass extraction of fexofenadine. Clin. Pharmacol. Ther. 74, 423–436 (2003).
Matsushima, S., Maeda, K., Ishiguro, N., Igarashi, T. & Sugiyama, Y. Investigation of the inhibitory effects of various drugs on the hepatic uptake of fexofenadine in humans. Drug Metab. Dispos. 36, 663–669 (2008).
Swift, B., Tian, X. & Brouwer, K. L. Integration of preclinical and clinical data with pharmacokinetic modeling and simulation to evaluate fexofenadine as a probe for hepatobiliary transport function. Pharm. Res. 26, 1942–1951 (2009).
Matsushima, S. et al. The inhibition of human multidrug and toxin extrusion 1 is involved in the drug–drug interaction caused by cimetidine. Drug Metab. Dispos. 37, 555–559 (2009).
Grahnen, A. Cimetidine bioavailability and variable renal clearance. Eur. J. Clin. Pharmacol. 27, 623–624 (1984).
Grahnen, A., Jameson, S., Loof, L., Tyllstrom, J. & Lindstrom, B. Pharmacokinetics of cimetidine in advanced cirrhosis. Eur. J. Clin. Pharmacol. 26, 347–355 (1984).
Grahnen, A., Von Bahr, C., Lindstroem, B. & Rosen, A. Bioavailability and pharmacokinetics of cimetidine. Eur. J. Clin. Pharmacol. 16, 335–340 (1979).
Collett, A., Higgs, N. B., Sims, E., Rowland, M. & Warhurst, G. Modulation of the permeability of H2 receptor antagonists cimetidine and ranitidine by P-glycoprotein in rat intestine and the human colonic cell line Caco-2. J. Pharmacol. Exp. Ther. 288, 171–178 (1999).
Sun, D. et al. Comparison of human duodenum and Caco-2 gene expression profiles for 12,000 gene sequences tags and correlation with permeability of 26 drugs. Pharm. Res. 19, 1400–1416 (2002).
Sun, W., Wu, R. R., van Poelje, P. D. & Erion, M. D. Isolation of a family of organic anion transporters from human liver and kidney. Biochem. Biophys. Res. Commun. 283, 417–422 (2001).
Takamatsu, N. et al. Human jejunal permeability of two polar drugs: cimetidine and ranitidine. Pharm. Res. 18, 742–744 (2001).
Jantratid, E. et al. Biowaiver monographs for immediate release solid oral dosage forms: cimetidine. J. Pharm. Sci. 95, 974–984 (2006).
Christians, U., Jacobsen, W., Benet, L. Z. & Lampen, A. Mechanisms of clinically relevant drug interactions associated with tacrolimus. Clin. Pharmacokinet. 41, 813–851 (2002).
Floren, L. C. et al. Tacrolimus oral bioavailability doubles with coadministration of ketoconazole. Clin. Pharmacol. Ther. 62, 41–49 (1997).
Fricker, G., Drewe, J., Huwyler, J., Gutmann, H. & Beglinger, C. Relevance of P-glycoprotein for the enteral absorption of cyclosporin A: in vitro–in vivo correlation. Br. J. Pharmacol. 118, 1841–1847 (1996).
Glavinas, H., Krajcsi, P., Cserepes, J. & Sarkadi, B. The role of ABC transporters in drug resistance, metabolism, and toxicity. Curr. Drug Deliv. 1, 27–42 (2004).
Kruijtzer, C. M., Beijnen, J. H. & Schellens, J. H. Improvement of oral drug treatment by temporary inhibition of drug transporters and/or cytochrome P450 in the gastrointestinal tract and liver: an overview. Oncologist 7, 516–530 (2002).
Kunta, J. R. & Sinko, P. J. Intestinal drug transporters: in vivo function and clinical importance. Curr. Drug Metab. 5, 109–124 (2004).
Lown, K. S. et al. Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine. Clin. Pharmacol. Ther. 62, 248–260 (1997).
Benet, L. Z., Cummins, C. L. & Wu, C. Y. Unmasking the dynamic interplay between efflux transporters and metabolic enzymes. Int. J. Pharm. 277, 3–9 (2004).
Ito, K., Kusuhara, H. & Sugiyama, Y. Effects of intestinal CYP3A4 and P-glycoprotein on oral drug absorption — theoretical approach. Pharm. Res. 16, 225–231 (1999).
Bardelmeijer, H. A. et al. Entrapment by Cremophor EL decreases the absorption of paclitaxel from the gut. Cancer Chemother. Pharmacol. 49, 119–125 (2002).
Stephens, R. H. et al. Resolution of P-glycoprotein and non-P-glycoprotein effects on drug permeability using intestinal tissues from mdr1a−/− mice. Br. J. Pharmacol. 135, 2038–2046 (2002).
Peltier, S., Oger, J. M., Lagarce, F., Couet, W. & Benoit, J. P. Enhanced oral paclitaxel bioavailability after administration of paclitaxel-loaded lipid nanocapsules. Pharm. Res. 23, 1243–1250 (2006).
Walle, U. K. & Walle, T. Taxol transport by human intestinal epithelial Caco-2 cells. Drug Metab. Dispos. 26, 343–346 (1998).
Sandstrom, M., Simonsen, L. E., Freijs, A. & Karlsson, M. O. The pharmacokinetics of epirubicin and docetaxel in combination in rats. Cancer Chemother. Pharmacol. 44, 469–474 (1999).
Strum, W. B. A pH-dependent, carrier-mediated transport system for the folate analog, amethopterin, in rat jejunum. J. Pharmacol. Exp. Ther. 203, 640–645 (1977).
Yokooji, T., Mori, N. & Murakami, T. Site-specific contribution of proton-coupled folate transporter/haem carrier protein 1 in the intestinal absorption of methotrexate in rats. J. Pharm. Pharmacol. 61, 911–918 (2009).
Lennernas, H. et al. The effect of L-leucine on the absorption of levodopa, studied by regional jejunal perfusion in man. Br. J. Clin. Pharmacol. 35, 243–250 (1993).
Biegel, A. et al. Three-dimensional quantitative structure–activity relationship analyses of b-lactam antibiotics and tripeptides as substrates of the mammalian H+/peptide cotransporter PEPT1. J. Med. Chem. 48, 4410–4419 (2005).
Tannergren, C., Bergendal, A., Lennernas, H. & Abrahamsson, B. Toward an increased understanding of the barriers to colonic drug absorption in humans: implications for early controlled release candidate assessment. Mol. Pharm. 6, 60–73 (2009).
Skold, C. et al. Presentation of a structurally diverse and commercially available drug data set for correlation and benchmarking studies. J. Med. Chem. 49, 6660–6671 (2006).
Adachi, Y., Suzuki, H. & Sugiyama, Y. Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm. Res. 18, 1660–1668 (2001).
Shitara, Y., Sato, H. & Sugiyama, Y. Evaluation of drug–drug interaction in the hepatobiliary and renal transport of drugs. Annu. Rev. Pharmacol. Toxicol. 45, 689–723 (2005).
Maeda, K., Suzuki, H. & Sugiyama, Y. Hepatic transport. Methods Princ. Med. Chem. 40, 277–332 (2009).
Hosea, N. A. et al. Prediction of human pharmacokinetics from preclinical information: comparative accuracy of quantitative prediction approaches. J. Clin. Pharmacol. 49, 513–533 (2009).
Seelig, A. How does P-glycoprotein recognize its substrates? Int. J. Clin. Pharmacol. Ther. 36, 50–54 (1998).
Seelig, A. & Landwojtowicz, E. Structure–activity relationship of P-glycoprotein substrates and modifiers. Eur. J. Pharm. Sci. 12, 31–40 (2000).
Maher Doan, K. M. et al. Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J. Pharmacol. Exp. Ther. 303, 1029–1037 (2002).
Adachi, Y., Suzuki, H. & Sugiyama, Y. Quantitative evaluation of the function of small intestinal P-glycoprotein: comparative studies between in situ and in vitro. Pharm. Res. 20, 1163–1169 (2003).
Poulin, P. & Theil, F. P. A priori prediction of tissue:plasma partition coefficients of drugs to facilitate the use of physiologically-based pharmacokinetic models in drug discovery. J. Pharm. Sci. 89, 16–35 (2000).
Schinkel, A. H. et al. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood–brain barrier and to increased sensitivity to drugs. Cell 77, 491–502 (1994).
Shitara, Y., Horie, T. & Sugiyama, Y. Transporters as a determinant of drug clearance and tissue distribution. Eur. J. Pharm. Sci. 27, 425–446 (2006).
Ieiri, I., Higuchi, S. & Sugiyama, Y. Genetic polymorphisms of uptake (OATP1B1, 1B3) and efflux (MRP2, BCRP) transporters: implications for inter-individual differences in the pharmacokinetics and pharmacodynamics of statins and other clinically relevant drugs. Expert Opin. Drug Metab. Toxicol. 5, 703–729 (2009).
Chou, C., McLachlan, A. J. & Rowland, M. Membrane permeability and lipophilicity in the isolated perfused rat liver: 5-ethyl barbituric acid and other compounds. J. Pharmacol. Exp. Ther. 275, 933–940 (1995).
Huang, L. et al. Relationship between passive permeability, efflux, and predictability of clearance from in vitro metabolic intrinsic clearance. Drug Metab. Dispos. 38, 223–231 (2009).
Fagerholm, U. Prediction of human pharmacokinetics — renal metabolic and excretion clearance. J. Pharm. Pharmacol. 59, 1463–1471 (2007).
Abrahamsson, B. & Lennernaes, H. Application of the biopharmaceutics classification system now and in the future. Methods Princ. Med. Chem. 40, 523–558 (2009).
Balimane, P. V., Han, Y. H. & Chong, S. Current industrial practices of assessing permeability and P-glycoprotein interaction. AAPS J. 8, E1–13 (2006).
Ganapathy, M. E., Huang, W., Wang, H., Ganapathy, V. & Leibach, F. H. Valacyclovir: a substrate for the intestinal and renal peptide transporters PEPT1 and PEPT2. Biochem. Biophys. Res. Commun. 246, 470–475 (1998).
Han, H. et al. 5′-amino acid esters of antiviral nucleosides, acyclovir, and AZT are absorbed by the intestinal PEPT1 peptide transporter. Pharm. Res. 15, 1154–1159 (1998).
Mealey, K. L., Bentjen, S. A., Gay, J. M. & Cantor, G. H. Ivermectin sensitivity in collies is associated with a deletion mutation of the mdr1 gene. Pharmacogenetics 11, 727–733 (2001).
Testa, B. in Comprehensive Medicinal Chemistry II Vol. 5 (eds. Testa, B. & van de Waterbeemd, H.) 1009–1041 (Elsevier Science, New York, 2006).
Watanabe, T., Kusuhara, H., Maeda, K., Shitara, Y. & Sugiyama, Y. Physiologically based pharmacokinetic modeling to predict transporter-mediated clearance and distribution of pravastatin in humans. J. Pharmacol. Exp. Ther. 328, 652–662 (2009).
Winterhalter, M. Black lipid membranes. Curr. Opin. Colloid Interface Sci. 5, 250–255 (2000).
Balon, K., Riebesehl, B. U. & Muller, B. W. Drug liposome partitioning as a tool for the prediction of human passive intestinal absorption. Pharm. Res. 16, 882–888 (1999).
Harrigan, P. R., Wong, K. F., Redelmeier, T. E., Wheeler, J. J. & Cullis, P. R. Accumulation of doxorubicin and other lipophilic amines into large unilamellar vesicles in response to transmembrane pH gradients. Biochim. Biophys. Acta 1149, 329–338 (1993).
Yan, E. C. & Eisenthal, K. B. Effect of cholesterol on molecular transport of organic cations across liposome bilayers probed by second harmonic generation. Biophys. J. 79, 898–903 (2000).
Xiang, T. X. & Anderson, B. D. The relationship between permeant size and permeability in lipid bilayer membranes. J. Membr. Biol. 140, 111–122 (1994).
Ahlin, G. et al. Structural requirements for drug inhibition of the liver specific human organic cation transport protein. J. Med. Chem. 51, 5932–5942 (2008).
Pedersen, J. M. et al. Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2). J. Med. Chem. 51, 3275–3287 (2008).
Palm, K., Stenberg, P., Luthman, K. & Artursson, P. Polar molecular surface properties predict the intestinal absorption of drugs in humans. Pharm. Res. 14, 568–571 (1997).
Chen, X., Murawski, A., Patel, K., Crespi, C. L. & Balimane, P. V. A novel design of artificial membrane for improving the parallel artificial membrane permeability assay model. Pharm. Res. 25, 1511–1520 (2008).
Acknowledgements
This paper is the joint effort of several colleagues from academia and the pharmaceutical industry working on a topic of common interest. We have to thank all involved colleagues for rapid feedback to support this task. We have to thank H. Kubinyi for comments at the initial phase of this activity.
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Supplementary information
Supplementary information S1 (Table)
Literatures supporting the evidence of CM transport (PDF 470 kb)
Glossary
- Active transport
-
An energy dependent, carrier protein-mediated transport process that can be against a concentration gradient.
- Area under the plasma concentration–time curve
-
(AUC). A measure of how much of an administered drug reaches the bloodstream in a defined period of time.
- Bioavailability
-
In this article, bioavailability means absolute bioavailability. Bioavailability describes the fraction of an administered dose (unchanged drug) that reaches the systemic circulation. Intravenously administered drugs by definition have a bioavailability of 100%. Other routes of administration may lead to lower bioavailability, usually expressed by a ratio or percentage of the maximum value.
- Biopharmaceutics classification system
-
(BCS). A classification system for drug molecules that considers solubility and permeation. There are four classes: BCS class I (molecules have high permeation/high solubility), BCS class II (molecules have high permeation/low solubility), BCS class III (molecules have low permeation/high solubility) and BCS class IV (molecules have low permeation/low solubility). Secondary factors considered in BCS include the rate of dissolution and the pH.
- Black lipid membrane
-
A single bilayer phospholipid membrane and optically black in appearance. It slowly forms when a small quantity of an egg lecithin dissolved in n-decane is placed over a small hole in a thin sheet of Teflon suspended in an aqueous buffer solution. Such membranes have been viewed as useful models of the more complex natural membranes.
- Caco-2 cells
-
An immortalized line of heterogeneous human epithelial colorectal adenocarcinoma cells used as a drug transport model for assessing intestinal absorption. Transport measurements can be performed in two directions: apical to basolateral or basolateral to apical.
- Carrier-mediated transport
-
This refers to active or facilitated transport that has a limited capacity and thus is saturable and subject to inhibition.
- CYP3A4
-
(Cytochrome P450 3A4). The most important member of the cytochrome P450 mixed-function oxidase system. It is involved in the metabolism of xenobiotics. CYP3A4 metabolism can occur in the gut wall and in the liver.
- Efflux ratio
-
(EfR). The ratio of the apparent permeation of a compound in the absorptive (apical to basolateral) direction to that in the secretory (basolateral to apical) direction, as determined in cell-based experiments. The EfR is used to determine possible active transport.
- Fa
-
The fraction of a dose of drug that is absorbed after oral administration. Fα depends on membrane permeance, solubility and the dissolution rate of a compound. It is expressed as a percentage.
- First pass metabolism
-
After intestinal absorption, drug molecules first pass through the liver before entering the systemic circulation. During this process, the drug can be metabolized in the liver and the systemic bioavailability can be reduced.
- Lipophilicity
-
The affinity of a compound for a lipid environment, for example, the hydrocarbon core of a phospholipid bilayer. It can also be described as the inter-molecular interaction between a compound and the solvent environment, such as the total hydrogen bond strength and dipole/polarizability.
- Log Doct
-
The octanol–water apparent partition coefficient at a certain pH. Both dissociated and undissociated (uncharged) molecular species are taken into account. In this article, when log Doct is less than zero, it is referred to as having low lipophilicity, when log Doct is greater than zero but less than 2, it is referred to as having moderate lipophilicity and when log Doct is greater than 2 it is referred to as having high lipophilicity.
- Log Poct
-
The octanol–water partition coefficient of a compound (neutral form). This parameter is most widely used as a whole molecule lipophilicity parameter.
- Oral bioavailability
-
The fraction or percentage of a drug that reaches the systemic circulation following oral administration. It is determined by the fraction absorbed and the fraction not metabolized in the gut wall and in the liver.
- P app
-
(Permeability coefficient). The apparent permeation for example, in Caco-2 cell-based permeation assays. Papp is the sum of passive transport and carrier-mediated transport when the effect of the aqueous boundary layer and the paracellular pathway is neglected.
- Passive transport
-
This refers to the movement of a permeant across a membrane from a region of high concentration to that of low concentration by a process of diffusion. The rate of passive transport is proportional to the concentration gradient of the permeant across the membrane.
- P eff
-
(Effective intestinal membrane permeation). Peff is measured by an in vivo experiment, for example, the in situ perfusion method. Peff is the sum of passive transport and carrier-mediated transport.
- P-glycoprotein
-
(P-gp). Also called ABCB1, P-gp is a protein involved in active efflux transport processes.
- pH partition theory
-
A theory that describes passive transport based on the pH of the aqueous phase, the dissociation constant (pKa) and the lipophilicity of a permeant. It states that an ionizable drug moves across a membrane by passive diffusion as its uncharged form, depending on its lipophilicity.
- pKa
-
The dissociation constant pKa for an ionizable molecule is the pH at which it would be ionized by 50%. The degree (%) of ionization is pH dependent. For an acid it decreases by lowering pH. For a base it increases by lowering pH.
- Tissue distribution coefficient
-
This represents the degree of drug molecule distributing into a tissue. This value depends on both passive transport and carrier-mediated transport across the cellular membrane of the tissue.
- Total permeation
-
This refers to the combination of passive transport and carrier-mediated transport processes.
- Ussing chamber
-
An instrument used to measure transport (for example, of drugs) across epithelial barriers. A sheet of epithelia (for example, intestinal mucosa) is clamped between two chambers and drug transport across the epithelia is measured.
Rights and permissions
About this article
Cite this article
Sugano, K., Kansy, M., Artursson, P. et al. Coexistence of passive and carrier-mediated processes in drug transport. Nat Rev Drug Discov 9, 597–614 (2010). https://doi.org/10.1038/nrd3187
Issue Date:
DOI: https://doi.org/10.1038/nrd3187
This article is cited by
-
Integrated profiling identifies CACNG3 as a prognostic biomarker for patients with glioma
BMC Cancer (2023)
-
Unravelling the Hepatic Elimination Mechanisms of Colistin
Pharmaceutical Research (2023)
-
Prediction of Oral Drug Absorption in Rats from In Vitro Data
Pharmaceutical Research (2023)
-
Design, Synthesis, Drug-Likeness and In Silico Prediction of Polycyclic Aromatic Schiff base Tethered Organosilatranes
Silicon (2023)
-
Targeted CRISPR activation and knockout screenings identify novel doxorubicin transporters
Cellular Oncology (2023)